News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kineta Inc. Announces Enrollment Of First Subject In 1B Clinical Trial



11/26/2013 9:25:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical disease areas, announced today that it has enrolled the first subject in a U.S. Phase 1B clinical trial of its lead drug, ShK-186, a novel immune-sparing therapeutic in development for a variety of autoimmune diseases. A successful Phase 1A safety trial was completed in March.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES